These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3433720)

  • 1. [Safety of biologicals produced in continuous cell cultures].
    Vopr Virusol; 1987; 32(5):631-2. PubMed ID: 3433720
    [No Abstract]   [Full Text] [Related]  

  • 2. [Transforming activity of DNA and proteins in continuous cell cultures and the safety of biologicals].
    Bektimitov TA
    Vopr Virusol; 1987; 32(5):519-24. PubMed ID: 3324478
    [No Abstract]   [Full Text] [Related]  

  • 3. Biologicals: an attempt at classification and its implication for the viral safety of products.
    Horaud F
    Dev Biol Stand; 1993; 81():17-24. PubMed ID: 8174800
    [No Abstract]   [Full Text] [Related]  

  • 4. WHO requirements for the use of animal cells as in vitro substrates for the production of biologicals (Requirements for biological susbstances no. 50).
    Grachev V; Magrath D; Griffiths E
    Biologicals; 1998 Sep; 26(3):175-93. PubMed ID: 10208720
    [No Abstract]   [Full Text] [Related]  

  • 5. Introductory remarks: viral safety of biologicals.
    Horaud F
    Dev Biol Stand; 1991; 75():3-7. PubMed ID: 1794630
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety-related regulatory actions for biologicals approved in the United States and the European Union.
    Giezen TJ; Mantel-Teeuwisse AK; Straus SM; Schellekens H; Leufkens HG; Egberts AC
    JAMA; 2008 Oct; 300(16):1887-96. PubMed ID: 18940975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory philosophy and acceptability of cells for the production of biologicals.
    Petricciani JC
    Dev Biol Stand; 1991; 75():9-15. PubMed ID: 1794634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acceptability of cell substrates for production of biologicals. Report of a WHO Study Group on Biologicals.
    World Health Organ Tech Rep Ser; 1987; 747():1-29. PubMed ID: 3107222
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks?
    Subramaniam K; Yeung D; Grimpen F; Joseph J; Fay K; Buckland M; Talaulikar D; Elijah J; Clarke AC; Pavli P; Moore J
    Intern Med J; 2014 Mar; 44(3):287-90. PubMed ID: 24621284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction to the issues: detection of retroviruses and associated risks.
    Marcus-Sekura CJ
    Dev Biol Stand; 1992; 76():137-40. PubMed ID: 1478334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Symposium on Continuous Cell Lines as Substrates for Biologicals. Arlington, Virginia, USA (Washington, D.C.), May 26-29, 1988. Proceedings.
    Dev Biol Stand; 1989; 70():1-304. PubMed ID: 2759343
    [No Abstract]   [Full Text] [Related]  

  • 12. Transmissible spongiform encephalopathies and the safety of naturally-derived biologicals.
    Di Martino A
    Biologicals; 1993 Mar; 21(1):61-6. PubMed ID: 8217119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Commentary: surveillance of reactions to biologicals.
    Hannik CA
    Bull World Health Organ; 1977; 55 Suppl 2(Suppl 2):163-5. PubMed ID: 305309
    [No Abstract]   [Full Text] [Related]  

  • 14. Risk assessment related to veterinary biologicals: side-effects in target animals.
    Martinod S
    Rev Sci Tech; 1995 Dec; 14(4):979-89. PubMed ID: 8639966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologics safety preclinical, clinical and regulatory.
    Hennig R
    Expert Opin Drug Saf; 2003 Nov; 2(6):609-11. PubMed ID: 14585069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of biologicals by plant cell cultures.
    Dougall DK
    Adv Exp Med Biol; 1979; 118():135-52. PubMed ID: 386723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics.
    Vargas HM; Bass AS; Breidenbach A; Feldman HS; Gintant GA; Harmer AR; Heath B; Hoffmann P; Lagrutta A; Leishman D; McMahon N; Mittelstadt S; Polonchuk L; Pugsley MK; Salata JJ; Valentin JP
    J Pharmacol Toxicol Methods; 2008; 58(2):72-6. PubMed ID: 18508287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complications in surgery for Crohn's disease after preoperative antitumour necrosis factor therapy.
    Myrelid P; Marti-Gallostra M; Ashraf S; Sunde ML; Tholin M; Oresland T; Lovegrove RE; Tøttrup A; Kjaer DW; George BD
    Br J Surg; 2014 Apr; 101(5):539-45. PubMed ID: 24615529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell substrates. Their use in the production of vaccines and other biologicals. Past achievements - future expectations.
    Meyer HM
    Adv Exp Med Biol; 1979; 118():1-5. PubMed ID: 495259
    [No Abstract]   [Full Text] [Related]  

  • 20. [Discontinuation of biologicals in rheumatoid arthritis after acquiring remission? Yes].
    Rubbert-Roth A
    Dtsch Med Wochenschr; 2011 Aug; 136(33):1674. PubMed ID: 21833889
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.